UBX | Unity Biotechnology (NASDAQ:UBX) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Unity Biotechnology (NASDAQ:UBX) from a hold rating to a buy rating in a research report report published on Saturday, Zacks.com reports.Zacks Investment Research currently has $4.75 price objective on the stock.According to Zacks, “UNITY Biotechnology Inc.develops therapeutics which prevents, halts and reverses various diseases.The company’s […]Daily Political

UBX | Zacks Investment Research Upgrades Unity Biotechnology (NASDAQ:UBX) to Buy

Unity Biotechnology (NASDAQ:UBX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Zacks.com reports.The firm currently has a $4.75 price target on the stock.Zacks Investment Research‘s target price indicates a potential upside of 12.83% from the company’s previous close.According to Zacks, […]The Olympia Report

UBX | Unity Biotechnology (NASDAQ:UBX) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Unity Biotechnology (NASDAQ:UBX) posted its earnings results on Wednesday.The company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.07), MarketWatch Earnings reports.NASDAQ:UBX traded up $0.06 during midday trading on Thursday, hitting $4.31.9,600 shares of the stock were exchanged, compared to its average volume of 707,422.The […]The Olympia Report